Position bei Pediapharm verdoppelt.
Produkte sind einige Zugelassen, auf dem Markt bzw. bei einigen wird die Vermarktung begonnen:
NYDA:57% increase from NYDA®, following the 55% growth from last fiscal year / will reach the $6-8 million of annual revenue by 2017" http://www.pedia-pharm.com/en/press-releases/pediapharm-announces-first-quarter-financial-results-increase-of-47-in-revenue-and-operating-profit-of-1-7-million/ , http://www.marketwired.com/press-release/...x-venture-pdp-2027297.htm
Naproxen:110% increase from Naproxen Suspension after one year of detailing to physicians -->76M Market in CA (http://www.marketwired.com/press-release/pediapharm-inc-announces-the-launch-of-pediapharm-naproxen-suspension-in-canada-tsx-venture-pdp-1989010.htm http://www.pedia-pharm.com/en/press-releases/...ofit-of-1-7-million/)
Rupatadine:On July 21, 2016, the Company announced Health Canada’s approval of rupatadine -->130M Market in CA http://www.pedia-pharm.com/en/press-releases/pediapharm-announces-first-quarter-financial-results-increase-of-47-in-revenue-and-operating-profit-of-1-7-million/
Relaxa: Under the terms of the licensing agreement, Pediapharm has the exclusive right to manufacture, promote, market, sell and distribute the product globally.
Annual sales of Relaxa, based on the trend of the last 12 months, is approximately $3-million, which will have an immediate impact on our top and bottom line and importantly, Relaxa has a strategic commercial fit with our signature product, NYDA.
Cash ist auch genügend vorhanden: The Company has $6,499,670 of cash and cash equivalents as of June 30, 2016
http://www.pedia-pharm.com/en/press-releases/pediapharm-announces-first-quarter-financial-results-increase-of-47-in-revenue-and-operating-profit-of-1-7-million/
Zudem stehen noch folgende Zulassungen an:
Otixal mit einem 25M Markt in CA im Q4 2016 Cuvposa mit einem 25M Markt in CA im Q2 2017 ...es wird auch weiter gearbeiten: CORE STRATEGY
•In-Licensing --> Obtain Exclusive Long Term Licensing/Distribution Agreements for Canada of Novel Drugs for Pediatrics. Ø Average Annual Peak Sales per Product: $ 5-8 Million
•Acquisitions --> Acquire Products that are already approved in Canada and with existing sales. Ø Immediate impact on both top and bottom-line
http://pedia-pharm.com/pdf/pediapharm-corporate-presentation-aug-2016-v5-pdf.pdf
Mit dem kürzlich abgeschlossenen Deal über Relaxa der kein Cash saugt, haben sie in meinen Augen bewiesen, dass weitere gute Deals ohne groß Cash auszugeben an Land gezogen werden können!
Desweiteren bleibt abzuwarten wie Knight noch mit in die Karten spielt, eine große Posi an Shares und Warrants wird ja gehalten (https://zephyr.bvdinfo.com/version-2016718/FullEditorialNews.serv?databaseContext=Deals&NewsId=25240&product=zephyrneo evtl. hat ja Paladin ein paar Pedi Medis )
...so mal wieder in einem Post die aktuelle Situation auf einen Stand gebracht.
|